Abstract Bladder cancer (BC) comprises 3% of all cancers and is particularly common in the
developed countries. Early diagnosis is an important necessity in improvement of BC …

The standard of care for non-muscle-invasive bladder cancer (NMIBC) is transurethral
resection followed by risk stratified use of intravesical immune-or chemotherapy and for …

Objective We conducted a systematic review and meta-analysis to assess the available
literature regarding the surgical and oncologic outcomes of patients undergoing salvage …

Bladder cancer (BC) is one of the most common tumours of the urinary system and is also
known as a highly malignant tumour. In addition to conventional diagnosis and treatment …

The efficacy of cisplatin-based chemotherapy in patients with bladder cancer is often limited
due to the development of therapeutic resistance. Our recent findings in bladder cancer …

Abstract Purpose of Review Bladder-sparing trimodality therapy (TMT) has become an
accepted alternative to cystectomy for selected muscle invasive bladder cancer (MIBC) …

Urothelial carcinoma of bladder is the second most prevalent genitourinary disease. It is a
highly heterogeneous disease as it represents a spectrum of neoplasms, including non …

Bladder cancer (BCa) is associated with significant morbidity, with development linked to
environmental, lifestyle, and genetic causes. Recurrence presents a significant issue and is …

In this cohort study of 144 miners, 72 miners worked underground (the study group) and 72
miners worked aboveground (the control group). Based on questionnaire data and of radon …

Bladder cancer (BC), a urologic disease, commonly occurs globally and is very invasive.
Patients with invasive BC have low 5-year survival rate. Hence, the mechanisms underlying …